Back to search
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trials you may qualify forThis phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetocl…
Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies. After cent…
The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic leu…
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the opt…
Adult patients with refractory or relapsed CD123+ hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leuk…
This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: *…
This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients wit…
This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and ant…